Acquired Company
Amgen acquired Horizon Therapeutics plc on 10/6/2023 for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
Acuired by Amgen 10/3/23. Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise and courages to bring clinically meaningful therapies to patients. The Company believes science and compassion must work together to transform lives. Show more
Start AI Chat
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$116.30
Open
$116.30
Volume
N/A
Day Range
$116.30 - $116.30
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
1.18%
Institutional Own.
-
Qtr Updated
06/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|